Tests afimkibart in adults with moderately to severely active Crohn's disease
Tests afimkibart against placebo in people with moderately to severely active Crohn's disease.
Plain-language title generated from the registry record
Registry title: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Key facts
- Where
- Bristol, Bury, Llanrhystud, London, Newcastle upon Tyne, and Stockport, United KingdomSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with moderately to severely active Crohn's disease. It tests a drug called afimkibart (RO7790121) against a placebo.
- Age
- 16 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Confirmed Crohn's disease that is moderately to severely active.
- Earlier treatment
- People must have had an inadequate response, lost response, or could not tolerate at least one protocol-specified conventional or advanced Crohn's therapy. People cannot join if they had protocol-specified prohibited medicines, including any anti-TL1A therapy.
Main reasons for not taking part
- Ulcerative colitis or other types of colitis
- 3 or more bowel resections, short bowel syndrome, or an ileostomy, colostomy or ileoanal pouch
- Abscess, certain fistulas, or symptomatic bowel strictures
- Cancer of the gastrointestinal tract, or most other past cancers
- Infection with C. difficile, CMV, HIV, hepatitis B or C, or active or inadequately treated tuberculosis
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 80 years old?
Source: NCT06819891, who can take part
Where in United Kingdom
- Southmead HospitalBristol, United KingdomTaking people
- Fairfield General HospitalBury, United KingdomTaking people
- Bronglais General HospitalLlanrhystud, United KingdomTaking people
- Royal London HospitalLondon, United KingdomTaking people
- Royal Victoria InfirmaryNewcastle upon Tyne, United KingdomTaking people
- Stepping Hill HospitalStockport, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT06819891EU 2024-513054-30-00
- Record updated
- 26 October 2026
- Original description
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).Read full original descriptionShow less
A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Inclusion: Confirmed diagnosis of CD; Moderately to severely active CD; Bodyweight >= 40 kilogram (kg); Demonstrated inadequate response, loss of response and/or intolerance to at least one protocol-specified conventional or advanced CD therapy; Males and females of childbearing potential must meet protocol criteria for contraception requirements.
Exclusion: Current diagnosis of ulcerative colitis (UC) or indeterminate colitis, ischemic colitis, infectious colitis, radiation colitis, microscopic colitis; Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy; Participant with a history of >= 3 bowel resections (> 2 missing segments of the 5 following segments: terminal ilelium, right colon, transverse colon, sigmoid and left colon, and rectum); Diagnosis of short gut or short bowel syndrome; Presence of rectovaginal, enterovaginal, high output enterocutaneous fistula, enterovesical fistulas or perianal fistulas with >3 openings; Any past or current evidence of cancer of gastrointestinal tract, high-grade colonic dysplasia and participants with low-grade dysplasia are eligible if lesions have been completely removed; History of non-gastrointestinal cancer, with the exception of adequately treated non-metastatic basal cell or squamous cell skin cancer or in situ cervical cancer; Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV) during screening; Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB; Presence of an ileostomy, colostomy or ileoanal pouch; Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon; Presence of abdominal or perianal abscess; Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon; Current diagnosis or suspicion of primary sclerosing cholangitis; Pregnancy or breastfeeding, or intention of becoming pregnant during the study.